格隆汇2月27日丨恒昌集团国际(01421.HK)公告，截至2025年12月31日止六个月，集团大部分收益源自 中华人民共和国(「中国」)的太阳能电业务、配电系统及美容及保健产品。中国太阳能电业务、配电系 统及美容及保健产品贡献的收益分别占集团总收益约52.8%(29,900,000港元)、44.9%(25,400,000港元)及 2.3%(1,300,000港元)。 公司拥有人应占亏损为约1130万港元(截至2024年12月31日止六个月：亏损1630万港元)及母公司普通股 权持有人应占的每股基本亏损为6.8港仙(截至2024年12月31日止六个月：每股亏损12.8港仙)。该变动主 要由于(i)太阳能电业务分部业绩好转产生亏损约5,700,000港元(截至2024年12月31日止六个月：亏损 8,200,000港元)；(ii)美容及保健业务分部业绩好转产生亏损1,700,000港元(截至2024年12月31日止六个 月：亏损3,000,000港元)；及(iii)公司及其他未分配开支增加至约8,600,000港元(截至2024年12月31日止 六个月：7,600,000港元)的综合影响。 ...

格隆汇2月27日丨中国高精密(00591.HK)宣布，于2026年2月27日，董事会辖下环境、社会及管治委员会 (「ESG委员会」)已告成立。执行董事邹崇获委任为ESG委员会主席；及四名独立非执行董事(即吉勤 之、胡国清、陈玉晓及黄世震)获委任为ESG委员会成员。 ...

该集团是一家即将进入商业化阶段的生物製药公司。同源康生物为一家非全资附属公司，专注于双抗、 三抗及ADC，独立于集团的核心业务及营运。增资及先前增资预计将有助于为同源康生物产生营运资 金，同源康生物是一家处于早期阶段的初创企业，预计在实现商业化之前，其在不久的将来将有大量的 资金需求。因此，该等交易将使集团能够将其资源集中于集团营运的其他方面，使集团能够更好地管理 其营运，同时保留于同源康生物的重大权益及参与程度。 智通财经APP讯，同源康医药-B(02410)公布，于2026年2月27日(交易时段后)，现有股东(包括该公司)、 同源康生物及认购人(深圳创新资本、宁波红土、衢州启真、衢州高质量发展、长兴同源及深圳国海中 恒)订立增资合同，据此，订约方同意以总代价约人民币8350万元增加同源康生物的注册资本约人民币 649万元。增资完成后，同源康生物的总注册资本将由人民币1400万元增加至约人民币2049万元，而公 司于同源康生物的权益将由约57.14%减少至39.03%，且同源康生物将不再为集团的附属公司。 ...

Core Viewpoint - The company, Yidu Tech (02158), demonstrates strong confidence in its long-term value and the prospects of the AI healthcare industry through its ongoing share buyback program, having repurchased 322,000 shares at approximately HKD 5.99 per share, totaling nearly HKD 2 million on February 27 [1] Group 1: Share Buyback Activity - Yidu Tech has completed 19 share buybacks this year, with a total expenditure exceeding HKD 76 million [1] - The buyback actions are seen as a consistent strategy to reinforce the company's commitment to its value and the AI healthcare sector [1] Group 2: Industry Insights - According to a report by Zhonghang Securities, domestic and international healthcare companies are increasingly investing in AI products and services across various areas, including medical imaging, clinical decision support, precision medicine, health management, medical information technology, drug development, and medical robotics [1] - AI is evolving from a "technical assistance" role to becoming a core driver of "value reshaping" and "efficiency revolution" in the healthcare industry, with its commercial value permeating from research to clinical, payment, and patient levels [1] Group 3: Business Developments - Yidu Tech has made significant innovations, including the internal testing of its clinical evidence-based intelligent system "Yidu Zhixun" [1] - A project supported by Yidu Tech for infectious disease monitoring and early warning in Hainan Free Trade Port has been recognized at the national level, being included in the "2025 Data Element ×" competition award project case collection [1]

Core Viewpoint - China High Precision (00591) reported a significant decline in both revenue and net profit for the six months ending December 31, 2025, primarily due to project delays affecting sales in the industrial automation instrument sector, particularly in the oil and petrochemical industries [1] Financial Performance - Revenue for the period was 85.48 million, representing a year-on-year decrease of 26.48% [1] - Net profit was 3.788 million, down 76.04% compared to the previous year [1] - Earnings per share stood at 0.37 cents [1] Revenue Drivers - The decrease in revenue was mainly attributed to delays in projects leading to reduced sales of industrial automation instruments in the oil and petrochemical sectors [1] - This decline was partially offset by slight growth in contract manufacturing services for automation instruments and technology products [1] Challenges - The company faces multiple challenges due to the global economic uncertainty and the slowdown in economic growth, which has adversely impacted the industrial automation instrument sector [1] Net Profit Factors - The reduction in net profit was primarily due to decreased sales of industrial automation instruments and an increase in foreign exchange losses [1] - This decline was partially mitigated by increased other income from the reversal of provisions for Chinese medical insurance and housing provident fund, as well as a reversal of inventory write-downs amounting to approximately 764,000 RMB [1]

Core Viewpoint - The company, Yidu Tech (02158), demonstrates strong confidence in its long-term value and the prospects of the AI healthcare industry through its recent share buyback activities, totaling over 76 million HKD this year [1] Group 1: Share Buyback Activities - On February 27, Yidu Tech repurchased 322,000 shares at approximately 5.99 HKD per share, with a total expenditure of nearly 2 million HKD [1] - The company has completed 19 buybacks this year, reflecting its commitment to enhancing shareholder value [1] Group 2: Industry Trends - A report from Zhonghang Securities highlights that domestic and international healthcare companies are increasingly investing in AI products and services across various sectors, including medical imaging, clinical decision support, precision medicine, health management, medical information technology, drug development, and medical robotics [1] - AI is evolving from a "technical assistance" role to becoming a core driver of "value reshaping" and "efficiency revolution" in the healthcare industry, with its commercial value penetrating various stages from research to clinical, payment, and patient levels [1] Group 3: Business Developments - Yidu Tech has made significant innovations, including the internal testing of its clinical evidence-based intelligent system, "Yidu Zhixun" [1] - The company's project for infectious disease monitoring and early warning in Hainan Free Trade Port has been recognized at the national level, being included in the "2025 Data Element ×" competition award project case collection [1]

中国高精密(00591)发布公告，独立非执行董事陈玉晓先生已获指定为首席独立非执行董事，自2026年2 月27日起生效。 ...

Core Viewpoint - China High Precision (00591) reported a significant decline in both revenue and net profit for the six months ending December 31, 2025, primarily due to project delays affecting sales in the industrial automation instrument sector, particularly in the oil and petrochemical industries [1] Financial Performance - Revenue for the period was 85.48 million yuan, representing a year-on-year decrease of 26.48% [1] - Net profit was 3.788 million yuan, down 76.04% compared to the previous year [1] - Earnings per share stood at 0.37 cents [1] Contributing Factors - The decline in revenue was mainly attributed to delays in projects, which led to reduced sales of industrial automation instruments in the oil and petrochemical sectors [1] - The slight growth in revenue from contract manufacturing services for automation instruments and technology products partially offset the decline [1] - The decrease in net profit was influenced by reduced sales of industrial automation instruments and an increase in foreign exchange losses [1] - Other income increased due to the reversal of provisions for Chinese medical insurance and housing provident fund, as well as a reversal of inventory write-downs amounting to approximately 764,000 yuan [1]

Group 1 - The company, China High Precision (00591), announced the appointment of Mr. Chen Yuxiao as the Chief Independent Non-Executive Director, effective from February 27, 2026 [1]

Core Viewpoint - China High Precision (00591.HK) reported a significant decline in revenue and profit for the six months ending December 31, 2025, primarily due to reduced sales in industrial automation instruments and increased foreign exchange losses [1] Financial Performance - The group's revenue for the period was approximately RMB 85.48 million, representing a decrease of about 26.5% compared to the same period in 2024 [1] - Profit attributable to the company's owners was approximately RMB 3.788 million, down from RMB 15.81 million in the same period of 2024 [1] - Basic and diluted earnings per share were RMB 0.37, compared to RMB 1.52 for the six months ending December 31, 2024 [1] Revenue Drivers - The decline in revenue was mainly attributed to project delays that led to reduced sales of industrial automation instruments in the oil and petrochemical sectors [1] - This decline was partially offset by slight growth in contract manufacturing services for automation instruments and technical products [1] Market Challenges - The company continues to face multiple challenges in the industrial automation instrument sector due to the slowdown in economic growth and global economic uncertainties [1]